Latest news

• Amyloid-targeting Alzheimer's drug bapineuzumab in phase III failure

  The results have not come as a surprise, however, as several other drugs designed to target amyloid have already failed in trials - including Neurochem's Alzhemed (tramiprosate), Lundbeck/Myriad Genetics' Flurizan

• 2012: amyloid as Alzheimer’s target?

  The number of disappointments for amyloid-targeting drugs is fairly substantial. Two small-molecule candidates, Neurochem's Alzhemed (tramiprosate) and Lundbeck/Myriad Genetics' Flurizan (r-flurbiprofen), failed a few years ago,

• Signalling change

  Another once-promising anti-amyloid drug, tramiprosate, was also abandoned by Bellus Health due to inconclusive phase III study findings.

• Halted in its tracks

  Tramiprosate is a B-amyloid inhibitor that is currently in phase III development with Neurochem. ... Data presented at ICAD 2006 showed tramiprosate halts B-amyloid-induced neuronal cell death in rats.

• Dealing with dementia

  A promising late-stage candidate is Neurochem's Alzhemed (tramiprosate). This drug works by mimicking and binding to glycosaminoglycan (GAG), which promotes the formation of the amyloid-beta plaques.